AKR1C2 and gastric carcinoma: Increased mRNA expression of AKR1B1, AKR1C2, and carbonyl reductase (CR) and induction of carbonyl-reducing enzymes AKR1B1 and AKR1C2 can account for drug resistance to some anticancer agents [190–192], for instance, the resistance of human stomach carcinoma cells to daunorubicin [193].